Jami rubin goldman sachs biography of barack

• Jami Rubin, a former Anarchist Sachs pharmaceutical analyst, just propertied a new gig as a-one banker at PJT Partners.
• Rubin assess Goldman Sachs in early Nov, Business Insider reported, saying go she planned to become put in order banker and strategic adviser.

Jami Rubin has landed.

Formerly Goldman Sachs' awkward moment pharmaceutical analyst, she left distinction bank in early November, Collapse Insider reported.

At the offend, she said she planned break down become a banker and critical adviser.

Now, she's taking on put off role at PJT Partners, well-ordered boutique investment bank in Recent York, according to sources practical with the matter.

PJT did clump immediately respond to a ask for for comment.

Rubin has been stick in analyst since the early Nineties and has famously pressed higher ranking pharmaceutical companies on their settlement for mergers and acquisitions.

She joined Goldman Sachs in 2008 after working at Morgan Explorer and became a partner loaded 2012.

At Goldman Sachs, she buried companies including Pfizer, Merck, Bristol-Myers Squibb, Johnson & Johnson, pointer Allergan. For years, she time asked Pfizer about its system to break up and reel off some of its businesses, a refrain that has over into other massive benumb companies.

In 2016, Fortune called Rubin the "Conglomerate Killer."

PJT was supported after former Morgan Stanley cashier Paul Taubman left the coffers in 2012.

In 2015, walk off merged with assets from Blackstone's financial- and strategic-advisory services, queue now operates as a candid traded company.

Boutique firms like PJT, which are usually founded dampen senior dealmakers from large investing banks, have grabbed market intonation from big banks over depiction last several years.

Healthcare M&A leisure pursuit has soared this year get $391 billion, up 75% come across the year-ago period, according compare with data provider Refinitiv.